Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy

Anti-Cancer Drugs

Volumn 15, Issue 9, 2004, Pages 843-847

  Kruit, W H J ^a   Stoter, G ^a   Klijn, J G M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Aminoglutethimide; Androgen independent; Prostate cancer; Prostate specific antigen

Indexed keywords

AMINOGLUTETHIMIDE; HYDROCORTISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG RESPONSE; DRUG TOLERABILITY; ERYTHEMA; FEVER; GENERAL CONDITION IMPROVEMENT; HUMAN; LETHARGY; MALE; METASTASIS; NAUSEA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RADIODIAGNOSIS; RASH; SIDE EFFECT; SKIN TOXICITY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONFIDENCE INTERVALS; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 8344219790     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200410000-00004     Document Type: Article

References (30)

1. McLeod DG, O'Brien ME. Hormonal management of metastatic prostate cancer and quality of life issues. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (editors): Comprehensive Textbook of Genitourinary Oncology. Baltimore, MD: Williams & Wilkins; 1996, pp. 854-864.
2. Smith DC, Bahnson RR, Trump DL, Dawson NA, Trepel J. Management of hormone refractory disease. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (editors): Comprehensive Textbook of Genitourinary Oncology. Baltimore, MD: Williams & Wilkins; 1996, pp. 885-914.
3. Petrylak DP. Docetaxel (Taxotere) in hormone refractory prostate cancer. Semin Oncol 2000; 27(suppl 3):24-29.
4. Ferro MA, Gillatt D, Symes MO, et al. High dose intravenous estrogen therapy in advanced prostatic carcinoma: use of serum prostate-specific antigen to monitor response. Urology 1989; 43:134-138.
5. Kelly WK, Scher HI, Mazumdar M, et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone refractory prostate cancer. J Clin Oncol 1993; 11:607-615.
6. Smith DC, Dunn RL, Stawderman MS, et al. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998; 16:1835-1843.
7. Scher HI, Kelly WK, Zhang ZF, et al. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 1999; 91:244-251.
8. Halabi S, Conaway MR, Small EJ, Vogelzang NJ, Dawson NA. Prostate specific antigen as a predictor of survival in prostate cancer patients treated with second-line hormonal therapy (CALGB 9181). Prostate J 2001; 3:18-25.
9. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17:3461-3467.
10. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003; 21:383-391.
11. Scher HI, Eisenberger M, D'Amico AV, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004; 22:537-556.
12. Huggins C, Scott WW. Bilateral adrenalectomy in prostatic cancer: clinical features and urinary excretion of 17-ketosteroids and estrogens. Ann Surg 1945; 122:1031-1041.
13. Mahoney EM, Harrison JH. Bilateral adrenalectomy for palliative treatment of prostate cancer. J Urol 1954; 72:485.
14. Murphy GP, Reynoso G, Schoonees R, et al. Hypophysectomy and adrenalectomy for disseminated prostate carcinoma. J Urol 1971; 105:817-825.
15. Resnick MI, Grayhack JT. Treatment of stage IV carcinoma of the prostate. Urol Clin North Am 1975; 2:141-157.
16. Robinson MRG, Shearer RJ, Fergusson JD. Adrenal suppression in the treatment of carcinoma of the prostate. Br J Urol 1974; 46:555-559.
17. Sanford EJ, Drago JR, Rohner TJ, Santen R, Lipton A. Aminoglutethimide medical adrenalectomy for advanced prostatic carcinoma. J Urol 1976; 115:170-174.
18. Rostom AY, Folkes A, Lord C, Notley RG, Schweitzer FAW, White WF. Aminoglutethimide therapy for advanced carcinoma of the prostate. Br J Urol 1982; 54:552-555.
19. Ponder BAJ, Shearer RJ, Pocock RD, et al. Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer. Br J Cancer 1984; 50:757-763.
20. Drago JR, Santen RJ, Lipton A, et al. Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma. Cancer 1984; 53:1447-1450.
21. Murray R, Pitt P. Treatment of advanced prostatic cancer resistant to convential therapy, with aminoglutethimide. Eur J Cancer Clin Oncol 1985; 21:453-458.
22. Harnett PR, Raghavan D, Caterson I, et al. Aminoglutethimide in advanced prostatic carcinoma. Br J Urol 1987; 59:323-327.
23. Elomaa I, Taube T, Blomqvist C, Rissanen P, Rannikko S, Alfthan O. Aminoglutethimide for advanced prostatic cancer resistant to conventional hormonal therapy. Eur Urol 1988; 14:104-106.
24. Samojlik E, Lippman AJ, Kirschner MA, Ertel NH, Park Y, Szmal E. Medical adrenalectomy for advanced prostatic cancer: clinical and hormonal effects. Am J Clin Oncol 1988; 11:579-585.
25. Labrie F, Dupont A, Belanger A, et al. Anti-hormone treatment for prostate cancer relapsing after treatment with flutamide and castration. Addition of aminoglutethimide and low dose hydrocortisone to combination therapy. Br J Urol 1989; 63:634-638.
26. Chang AY, Bennett JM, Pandya KJ, Asbury R, McCune C. A study of aminoglutethimide and hydrocortisone in patients with advanced and refractory prostate carcinoma. Am J Clin Oncol 1989; 12:358-360.
27. Sartor O, Cooper M, Weinberger M, et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of 'hormone refractory' prostate cancer. J Natl Cancer Inst 1994; 86:222-227.
28. Dawson N, Figg WD, Brawley OW, et al. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. Clin Cancer Res 1998; 4:37-44.
29. Davies JH, Dowsett M, Jacobs S, Coombes RC, Hedley A, Shearer RJ. Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer. Br J Cancer 1992; 66:139-142.
30. Santen RJ, Petroni GR, Fisch MJ, Myers CE, Theodorescu D, Cohen RB. Use of the aromatase inhibitor Anastrozole in the treatment of patients with advanced prostate carcinoma. Cancer 2001; 92:2095-2101.